GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » QuidelOrtho Corp (NAS:QDEL) » Definitions » EV-to-EBIT

QuidelOrtho (QuidelOrtho) EV-to-EBIT

: 33.62 (As of Today)
View and export this data going back to 1992. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, QuidelOrtho's Enterprise Value is $5,036 Mil. QuidelOrtho's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $150 Mil. Therefore, QuidelOrtho's EV-to-EBIT for today is 33.62.

The historical rank and industry rank for QuidelOrtho's EV-to-EBIT or its related term are showing as below:

QDEL' s EV-to-EBIT Range Over the Past 10 Years
Min: -175.01   Med: 33.66   Max: 559.75
Current: 33.62

During the past 13 years, the highest EV-to-EBIT of QuidelOrtho was 559.75. The lowest was -175.01. And the median was 33.66.

QDEL's EV-to-EBIT is ranked worse than
75.05% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 19.21 vs QDEL: 33.62

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. QuidelOrtho's Enterprise Value for the quarter that ended in Dec. 2023 was $7,363 Mil. QuidelOrtho's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $150 Mil. QuidelOrtho's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.03%.


QuidelOrtho EV-to-EBIT Historical Data

The historical data trend for QuidelOrtho's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QuidelOrtho Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.80 6.87 5.48 10.11 49.15

QuidelOrtho Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.11 28.63 36.55 38.49 49.15

Competitive Comparison

For the Medical Devices subindustry, QuidelOrtho's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QuidelOrtho EV-to-EBIT Distribution

For the Medical Devices & Instruments industry and Healthcare sector, QuidelOrtho's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where QuidelOrtho's EV-to-EBIT falls into.



QuidelOrtho EV-to-EBIT Calculation

QuidelOrtho's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5035.674/149.8
=33.62

QuidelOrtho's current Enterprise Value is $5,036 Mil.
QuidelOrtho's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $150 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


QuidelOrtho  (NAS:QDEL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

QuidelOrtho's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=149.8/7362.59
=2.03 %

QuidelOrtho's Enterprise Value for the quarter that ended in Dec. 2023 was $7,363 Mil.
QuidelOrtho's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $150 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


QuidelOrtho EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of QuidelOrtho's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


QuidelOrtho (QuidelOrtho) Business Description

Traded in Other Exchanges
Address
9975 Summers Ridge Road, San Diego, CA, USA, 92121
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make better decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
Executives
Louise Brandy officer: SVP, Chief Information Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Patrick Klein officer: Chief Administrative Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Christopher M Smith director 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Edward L. Michael director 618 SHERIDAN SQUARE, EVANSTON IL 60202
William J. Ferenczy officer: SVP, Cardio/Metabolic Unit 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Werner Kroll officer: SVP, Research and Development 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Kenneth F Buechler director
Robert R. Schmidt director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tamara A. Ranalli officer: SVP, Molecular Bus. Unit 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Stephen H. Wise director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Robert Joseph Bujarski officer: See Remarks C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Wilkins Joseph D Jr. director 82414 PUCCINI DRIVE, INDIO CA 92203
Michelle A. Hodges officer: SVP, General Counsel 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Douglas C Bryant director, officer: Chairman & CEO C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Joseph M Busky officer: Chief Financial Officer 1717 DEERFIELD ROAD, DEERFIELD IL 60015